| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,214.2 | 1,105.2 |
| Gross profit | 764.3 | 683.4 |
| Profit before tax | 399.3 | 344.8 |
| Net income | 317.1 | 274.6 |
| EPS (diluted, $ a share) | $4.01 | $3.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +15.5% |
|---|---|
| Revenue, year on year | +9.9% |
| Gross margin | 62.9% |
| Operating margin | 33.1% |
10-Q filed with the SEC, NASDAQ: IDXX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Idexx Laboratories Inc: key numbers
- Share price
- $700.65Close, Nov 16
- Market cap
- $55.2B
- Shares outstanding
- 78.79MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Idexx Laboratories Inc
All →Idexx Laboratories Executive Chair of the Board Jonathan Jay Mazelsky Sells $17.7M of Stock
Jonathan Jay Mazelsky, Executive Chair of the Board, sold 25,140 shares of Idexx Laboratories Inc at $698.26 to $711.95 a share (average $703.19) in 13 transactions, worth $17.7M in total on Nov 4, 2026. Shares held after the trade: 83,803 (-0.4%).
- Value
- $17.7M
- Shares
- 25,140
- Average price
- $703.19
- Role
- Executive Chair of the Board
- Holding change
- -0.4%
- Trade date
- Nov 4, 2026
Idexx Laboratories EVP Michael Lane Sells $2.74M of Stock
Michael Lane, EVP, sold 3,979 shares of Idexx Laboratories Inc at $687.46 to $689.70 a share (average $688.64) in 3 transactions, worth $2.74M in total on Nov 4, 2026. Shares held after the trade: 4,076 (-29.2%).
- Value
- $2.74M
- Shares
- 3,978
- Average price
- $688.64
- Role
- EVP
- Holding change
- -29.2%
- Trade date
- Nov 4, 2026
Idexx Laboratories EVP, GC & Corporate Secretary Sharon E. Underberg Sells $6.13M of Stock
Sharon E. Underberg, EVP, GC & Corporate Secretary, sold 8,906 shares of Idexx Laboratories Inc at $688.25 to $690.02 a share (average $688.59) in 3 transactions, worth $6.13M in total on Nov 4, 2026. Shares held after the trade: 7,169 (-12.8%).
- Value
- $6.13M
- Shares
- 8,906
- Average price
- $688.59
- Role
- EVP, GC & Corporate Secretary
- Holding change
- -12.8%
- Trade date
- Nov 4, 2026
Idexx Laboratories Insider Daniel M. Junius Sells $845K of Stock
Daniel M. Junius sold 1,200 shares of Idexx Laboratories Inc at $701.68 to $705.78 a share (average $704.07) in 2 transactions, worth $845K in total on Nov 4, 2026. Shares held after the trade: 2,361 (-17.5%).
- Value
- $845K
- Shares
- 1,200
- Average price
- $704.07
- Holding change
- -17.5%
- Trade date
- Nov 4, 2026
Idexx Laboratories Financial Results
IDEXX Laboratories reported third quarter 2026 revenue of $1.21 billion, up 10% year-over-year, driven by strong growth in its Companion Animal Group. The company delivered EPS of $4.01 and raised its full-year 2026 revenue and EPS guidance based on strong recurring diagnostics performance.
- Term
- Q3 2026
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy. Innovations like IDEXX inVue Dx with FNA, and IDEXX Cancer Dx becoming a multi-cancer panel, are helping practices detect disease earlier and work more efficiently.”
Mike Erickson, President and Chief Executive Officer